By synergistically leveraging integrative multiomics frameworks, such as epigenomic, proteomic, and metabolomic profiling
There is: No evidence that Epitalon can shrink existing tumors in humans No human clinical trials testing its use in oncology No mechanistic studies confirming how Epitalon affects tumor microenvironments or immune evasion in vivo What we do have is a compelling preventive profile in animal models, especially where aging and genetic susceptibility intersect
PGI 2 is released in higher amounts in response to the binding of ligands, such as thrombin, arachidonic acid, histamine or serotonin
When impurities in the blood affect the sapta dhatus (seven bodily tissues) and lead to contamination, their essential qualities diminish, impairing their absorption and transformation
Its the most underrated longevity predictor